Kornimate/medical-research-clean huggingface dataset:
predicting successful sleep apnea treatment with acetazolamide in heart failure patients

Conditions: Heart Failures

Summary: the ultimate goal is to improve our understanding of the pathophysiology and resistance to effective treatment of sleep disordered breathing in patients with heart failure, with a focus on selecting patients that will benefit specifically from acetazolamide treatment. the study addresses three primary hypotheses: 1) acetazolamide treatment will reduce the apnea-hypopnea index and improve markers of heart-failure severity in heart-failure patients with sleep apnea. 2) acetazolamide will provide the greatest improvement in patients with the most severe ventilatory control instability (strongest chemoreflex response to carbon dioxide; highest loop gain). 3) acetazolamide will act primarily via stabilizing ventilatory control (reducing loop gain), rather than via improvement to upper airway anatomy, pulmonary congestion, and cardiac function.


Eligibility criteria:
inclusion criteria (heart failure patients) * left ventricular ejection fraction (ef) \<50%, or heart failure with preserved ef * age 18-89 exclusion criteria: * severe obstructive respiratory disease * unstable heart failure status * recent use of positive airway pressure therapy * current use of opioids, benzodiazepines * severe kidney disease * severe anemia
covid-19 thrombosis prevention trials: post-hospital thromboprophylaxis

Conditions: Covid19

Summary: a multicenter, adaptive, randomized platform trial evaluating the efficacy and safety of antithrombotic strategies in patients with covid-19 following hospital discharge

this study is an adaptive, prospective, randomized platform trial designed to compare the effectiveness and safety of antithrombotic therapy with no antithrombotic therapy after hospitalization for 48 hours or longer for covid-19. for stage 1 of this study, participants will be randomized to either prophylactic anticoagulation or matching placebo for 30 days, and then followed for an additional 60 days after the completion of treatment (total duration of follow-up, 90 days). the primary objective is to determine the most effective and safe antithrombotic strategy to prevent the composite outcome of symptomatic deep vein thrombosis, pulmonary embolism, other venous thromboembolism, ischemic stroke, myocardial infarction, other arterial thromboembolism, and all-cause mortality by 30 days following discharge from the hospital. biobanking of samples for future biomarker and mechanistic studies will be available for centers able to participate and collect samples from eligible participants. samples will be collected at the time of enrollment and after the completion of 30 days of therapy

Eligibility criteria:
inclusion criteria: * • age ≥ 18 years * pcr-positive covid-19 infection * hospitalized for two or more days exclusion criteria: * pre-existing indication for anticoagulation (e.g., pulmonary embolism or deep vein thrombosis; atrial fibrillation; mechanical cardiac valve) * contraindication to antithrombotic therapy (e.g., known bleeding within the last 30 days requiring emergency room presentation or hospitalization; major surgery within 14 days; ischemic stroke, intracranial bleed or neurosurgery within 3 months. * platelet count \< 50,000/mcl * hemoglobin \<8 gm/dl * renal insufficiency (egfr \< 30 ml/min/1.73 m2) * pregnancy * prison inmate * life expectancy less than 90 days * unwilling or unable to provide informed consent/unwilling or unable to complete the study protocol * dual antiplatelet therapy that cannot be discontinued * concomitant need for strong inducers/inhibitors of p-gp or cyp3a4
a korean post-marketing surveillance study on pergoveris® (follitropin alfa + lutropin alfa)

Conditions: Infertility

Summary: this prospective study collected safety information from more than 600 participants treated with pergoveris®. during the post-marketing surveillance (pms) period, data about the participant's background, participant's medical history, pergoveris® indication, prior infertility medication, pergoveris® treatment status, concomitant drugs, all adverse events (regardless of the causal relationship to pergoveris®) and efficacy (follicular growth and clinical pregnancy) were collected for study purposes.the post marketing surveillance was based on all cases treated with pergoveris®.


Eligibility criteria:
inclusion criteria: * participants, who were eligible for pergoveris® treatment according to the indication in the national label of pergoveris®. the national label approved by korea food \& drug administration is "pergoveris® in association with a follicle stimulating hormone(fsh) preparation was recommended for the stimulation of follicular development in women with severe luteinizing hormone (lh) and fsh deficiency. in clinical trials these participants were defined by an endogenous serum lh level less than (\<)1.2 international units per liter iu/l" exclusion criteria: * according to national label
a comparison of ultrasound guided genicular nerve blockade using current versus revised anatomical targets

Conditions: Knee Pain Chronic

Summary: comparison of effectiveness of ultrasound guided genicular nerve blockades and radio frequency stimulation


Eligibility criteria:
inclusion criteria: - exclusion criteria: * coagulation disorders * rheumatoid disorders * infections

Keywords: osteoarthritis radiofrequency ultrasound anatomical landmarks
comparison of ultrasound-guided perimeniscal steroid and 5% dextrose injections in knee osteoarthritis

Conditions: Gonarthrosis; Meniscus; Degeneration; Pain, Chronic

Summary: introduction: the primary goal of treating knee osteoarthritis is to reduce pain and improve the patient's quality of life. medial meniscal extrusion is a condition that is linked to pain and disability in knee osteoarthritis and can be identified through ultrasound. for patients with medial meniscal extrusion, perimeniscal corticosteroid injection has been shown to be a helpful addition to primary treatment for moderate to severe pain relief. dextrose prolotherapy has also been found to provide periarticular benefits for knee osteoarthritis. this study aims to compare the effectiveness of ultrasound-guided perimeniscal corticosteroid and perimeniscal dextrose injections in patients with osteoarthritis, medial knee pain, and medial meniscal extrusion. method: patients with medial knee pain and meniscal extrusion were randomly divided into two groups using the double-block randomization method. group 1 included 15 patients who were administered an ultrasound-guided perimeniscal steroid injection, while group 2 included 16 patients who were administered an ultrasound-guided perimeniscal dextrose injection. the patients' pain levels were evaluated using the visual analog pain scale (vas) and the western ontario and mcmaster universities osteoarthritis index (womac) before and one week, one month, and three months after the injection.


Eligibility criteria:
inclusion criteria: * grade 2-4 knee osteoarthritis, * aged 40 to 79 * chronic medial knee pain persisting for more than 3 months. * ultrasound screening found medial meniscal extrusion of more than 3 mm * a visual analog scale (vas) score of at least 4. exclusion criteria: a skin infection at the injection site, a prior history of inflammatory arthropathy, a prior history of knee injection within the last 3 months, knee synovitis pes anserine bursitis scheduled for surgery
response to pegylated interferon and ribavirin in chinese patients with chronic hepatitis c genotypes 1 versus 2/3 versus 6

Conditions: Chronic Hepatitis C

Summary: the chinese patients with chronic hepatitis c have a different genetic background, which had been demonstrated to significantly influence their responses to pegylated interferon and ribavirin. in this study, chinese patients with hepatitis c virus genotype 1, 2/3, 6 infection were treated with pegylated interferon and ribavirin. their response was compared amongst different genotypes.


Eligibility criteria:
inclusion criteria: * hcv rna is positive * treatment naive * come from china exclusion criteria: * active substance abuse * poorly controlled psychiatric disease * hbsag positive * anti-hiv positive * suffering from other significant concurrent medical conditions including chronic liver diseases

Keywords: peginterferon alfa-2a ribavirin
vitamin and oxygen interventions and cardiovascular events

Conditions: Postoperative Cardiac Complication

Summary: this study examines the risks and benefits of antioxidants and normal versus high inspiratory oxygen fraction during anaesthesia.

adult patients with risk factors for developing postoperative cardiac complications will be enrolled in the study. the patients will be randomised to receiving antioxidants or placebo perioperatively and 30% or 80% inspiratory oxygen concentration during anaesthesia and 2 hours postoperatively. the primary outcome is mins (myocardial injury after non-cardiac surgery). the antioxidants are ascorbic acid (vitamin c) 3 grams intravenously preoperatively and n-acetylcysteine 100 milligrams/kilogram body weight intravenous infusion for 4 hours, starting at the same time as anaesthesia. the study is a long-term follow-up study of the risk of mortality, mi and readmissions performed at 1 year after inclusion of the last patient. two other follow-up studies are planned: one investigation of ischaemic troponin elevations defined as peak troponin levels above the internationally defined thresholds without extracardiac causes; another investigating the intervention effects in the subgroup of patients undergoing vascular surgery with specific emphasis on episodes of intraoperative hypotension within the following thresholds: map below 70 mmhg, 65 mmhg, 60 mmhg and 55 mmhg.

Eligibility criteria:
inclusion criteria: all of the listed criteria (1.-4.) must be met. 1. age 45 years or above 2. elective or acute surgery in general anaesthesia 3. scheduled for abdominal, orthopaedic, or vascular surgery with expected surgery duration of one hour or more. 4. fulfil any 1 of the following 5 criteria: 1. - history of coronary artery disease including angina 2. - history of stroke 3. - undergoing vascular surgery 4. - history of peripheral arterial disease 5. - any 2 of the following 8 criteria: i. acute surgery ii. current or previous daily smoking iii. history of hypertension iv. diabetes mellitus requiring medical treatment v. history of transient cerebral ischemia vi. plasma creatinine \>175 µm vii. age 70 years or above viii. history of congestive heart failure exclusion criteria: 1. surgery within 30 days prior to operation 2. arterial oxygen saturation below 90% without oxygen supplementation 3. inability to give informed consent 4. drug allergy towards any of the drugs involved in the trial 5. previous treatment with bleomycin 6. pregnancy

Keywords: antioxidant hyperoxia troponin mins ascorbic acid n-acetylcysteine
treatment of anemia with intravenous iron in patients listed for orthotopic liver transplantation

Conditions: Liver Transplantation; Blood Loss

Summary: the aim of this study is to investigate whether therapy with intravenous iron carboxymaltose in patients with iron deficiency anemia (ida) listed for orthotopic liver transplantation (olt) increases hemoglobin concentrations and reduces intraoperative transfusion of packed red blood cells (prbcs). the investigators hypothesize that therapy with intravenous iron will increase hemoglobin concentrations and reduce intraoperative transfusion of prbcs in patients with ida listed for olt.


Eligibility criteria:
inclusion criteria: * patients listed for olt with positive screening for ida exclusion criteria: * age \<18 years * hemochromatosis * iron utilization disorders * non-ida * therapy with erythropoietin-stimulating agents or intravenous iron within 4 weeks prior to screening * previous allergic reactions against intravenous iron formulations * transfusion within 2 weeks prior to screening * complete portal vein thrombosis * high-urgency olt * pregnancy * sepsis or severe infection * immunosuppressive therapy

Keywords: liver anemia transplantation
safety and efficacy of the glucome app in patients with uncontrolled diabetes treated with mdi

Conditions: Diabetes Mellitus, Type 1 or 2

Summary: the study will evaluate the safety and efficacy of computerized glucome app in patients with uncontrolled diabetes treated with mdi.

glucome is an interactive system, which provides glucose management tools to both the patient and health care team (hct). the system includes a decision support system to be used by the hct aiming to aid clinical decision making with mathematical models. the system does not intend to replace clinical judgement and all recommendations are to be approved by the hct. forty (40) diabetic patients on multiple daily insulin injection (mdi) with abnormal hba1c and identified as potential end users of the device will be recruited to the study and screened according to the study inclusion and exclusion criteria. patient's daily blood glucose will be measured and the glucome app will give its recommendations for change in insulin dose, as well as recommendations for pre and post-meal carbohydrate and exercise. patient's daily blood glucose levels will be followed by the hct biweekly for 12 weeks and patients will be instructed to change their insulin doses according to the decision of the treating physician. at the end of the study, the hct's recommendations for treatment adjustment will be compared to those of the system for both safety and efficacy. study subjects and the hct will be asked to complete a questionnaire regarding the glucome system usability.

Eligibility criteria:
inclusion criteria: 1. both type 1 and type 2 diabetes 2. hba1c 7-11% 3. treated with mdi for at least 3 months 4. ability to use the system at home, mobile phone exclusion criteria: 1. active cad, cva during last 6 months 2. treatment with steroids or other glucose modifying drugs 3. chronic infection/cancer/other severe disease

Keywords: glucose blood measurements, glucometer, bgm, diabetes app
evaluation of smoked thc and cbd in men and women

Conditions: Drug Abuse; Intoxication by Drug; Impairment

Summary: the purpose of this study is to determine the pharmacokinetics and pharmacodynamics of inhaled cannabis with varying amounts of delta-9-tetrahydrocannabinol (thc), and cannabidiol (cbd) and to evaluate detection of recently smoked thc in oral fluid.

this double-blind placebo controlled, within-subject study study will assess testing devices that can measure biochemical markers in oral fluid and neurocognitive-performance markers of recent cannabis use. other pharmacodynamic effects of inhaled cannabis with cbd and thc will be determined and the pharmacokinetics of thc, cbd, and respective metabolites will be assessed in whole blood.

Eligibility criteria:
inclusion criteria: * male or non-pregnant and non-lactating females aged 21-55 years * report weekly-monthly use of cannabis (≤1 day per week) over the past month prior to screening, * not currently seeking treatment for their cannabis use * have a body mass index from 18.5 - 34kg/m2. * able to perform all study procedures * must be using a contraceptive (hormonal or barrier methods) exclusion criteria: * meeting dsm-v criteria for moderate to severe cannabis use disorder (cud) or any substance use disorder other than nicotine, caffeine * any other axis i disorder * report using other illicit drugs in the prior 4 weeks, other than cannabis. * current use of any medications that may affect study outcomes * if medical history, physical and psychiatric examination, or laboratory tests performed during the screening process are not within the normal range and / or reveal any significant illness (e.g., hypertension) as judged by the study physician and to put the participant at greater risk of experiencing adverse events due to completion of study procedures. * pregnancy is exclusionary due to the possible effects of the study medication on fetal development. * history of an allergic reaction or adverse reaction to cannabis is exclusionary. * history of respiratory illness or current respiratory illness * currently enrolled in another research protocol * not using a contraceptive method (hormonal or barrier methods) * the evaluating physician reviews all medical assessments along with medical history. any disorders that might make cannabis administration hazardous are exclusionary.

Keywords: cannabis thc cbd intoxication impairment
seasonal allergic rhinitis and driving ability

Conditions: Seasonal Allergic Rhinitis

Summary: on-the-road driving performance of untreated seasonal allergic rhinitis patients during the allergic season (exposed) is compared to driving performance outside the allergic season (in winter, not-exposed).

this study was set-up to examine whether untreated seasonal allergic rhinitis has an effect on driving ability. in addition to the driving tests, patients perform a memory test in the laboratory.

Eligibility criteria:
inclusion criteria: * outpatients with seasonal allergic rhinitis * a valid driver's licence * written informed consent * a t5ss score \>8 during the allergic season and \<3 in winter exclusion criteria: * use of medication or medical conditions that are known to affect driving ability * associated ent disease or asthma

Keywords: driving memory
diagnostic of infections following major abdominal surgery and burn injury

Conditions: Third Degree Burn; Second Degree Burn

Summary: this study was designed to investigate, if new biomarkers may improve the early diagnostic of infections following major abdominal surgery and severe burn injuries.


Eligibility criteria:
inclusion criteria: * patients with major abdominal surgery (e.g. gastrectomy, hemi-/colectomy, resection of sigma or rectum, resection of liver, esophagectomy) * patients following severe burn injury (burn surface area \>= 15%) * age \>= 18 years * informed consent exclusion criteria: * no informed consent * emergency surgery * immunocompromising diseases (e.g. hiv+, aids, lymphoma or nonhodgkin-lymphoma, autoimmune-diseases) * pre-existing liver or renal failure * chronic therapy with corticoids

Keywords: major abdominal surgery severe burn injury infection diagnostic
evaluation of brain damage due to coronary angioplasty in percutaneous intervention patients

Conditions: Silent Stroke; Coronary Disease

Summary: this study examines the formation mechanism and patient-related factors of silent cerebral infarcts, whose importance has become increasingly recognized in patients undergoing percutaneous coronary intervention.

this study was produced from the assistant's thesis and was previously accepted as a poster at europcr 2020. we recently completed the full-length article. this thesis study was supported by ondokuzmayis university.

Eligibility criteria:
inclusion criteria: * cto and non-cto patients undergoing percutaneous coronary intervention exclusion criteria: * baseline nse elevation * acute coronary syndromes or cardiac surgery within 4 weeks * patients with a cerebrovascular accident * intracranial hemorrhage * and head trauma * central nervous system tumor * degenerative central nervous system disorders and neuroendocrine tumors

Keywords: silent brain injury chronic total occlusion percutaneous coronary intervention neuron specific enolase
pk and safety of si-722 in ic/bps

Conditions: Interstitial Cystitis; Bladder Pain Syndrome

Summary: this study is designed randomized, double-blind, placebo-controlled trial in interstitial cystitis/bladder pain syndrome patients.


Eligibility criteria:
inclusion criteria: * males or females, ≥18 and ≤80 years of age * a score of 19 or greater on the bladder pain/interstitial cystitis symptom score (bpic-ss) exclusion criteria: * urinary tract infection ≤30 days * treatment with intravesical therapy ≤60 days * treatment with any opioid therapy ≤7 days * history of bladder hydrodistension ≤3 months * has cancer or a past history of any cancer ≤5 years * body mass index (bmi) ≥40 kg/m2

Keywords: bladder intravesical injection interstitial cystitis
efficacy and safety of artesunate-amodiaquine-methylene for malaria treatment in children

Conditions: Uncomplicated Falciparum Malaria

Summary: title: efficacy and safety of artesunate-amodiaquine combined with methylene blue for falciparum malaria treatment in african children: randomised controlled trial. design: mono-centre, two arms, open randomized controlled study in children with uncomplicated falciparum malaria in burkina faso. phase: phase ii. objectives: the primary objective of this trial is to study the efficacy and safety of the triple therapy artesunate (as) - amodiaquine (aq) - methylene blue (mb) given over three days in young children with uncomplicated falciparum malaria in burkina faso compared to the local standard three days artemisinin-based combination therapy (act) as-aq regimen. population: children aged 6-59 months with uncomplicated falciparum malaria from nouna hospital in north-western burkina faso. sample size: 180 patients (90 per study arm).


Eligibility criteria:
inclusion criteria: * 6-59 months old children (male and female) * weight ≥ 6kg * uncomplicated malaria caused by p. falciparum * asexual parasites ≥ 2 000/µl and ≤ 200 000/µl * axillary temperature ≥ 37.5°c or a history of fever during last 24 hours * burkinabe nationality * permanent residence in the study area with no intention of leaving during the surveillance period * informed consent exclusion criteria: * severe malaria (who 2000) * vomiting (3 or more within 24 hours before the visit) * any apparent significant disease, including severe malnutrition * a history of a previous, significant adverse reaction to either of the study drugs * anaemia (haemoglobin \< 7 g/dl) * treated in the same trial before * all modern antimalarial treatment prior to inclusion (last seven days) * simultaneous participation in another investigational study * treatment with other investigational drugs

Keywords: children
rational approach to a unilateral pleural effusion

Conditions: Lung Neoplasms

Summary: recurrent unilateral, non-infectious pleural exudate is suspicious for primary or secondary pleural malignancy. both conditions are associated with 5-year survival of 10%. work-up is difficult, as the pleural surface is large and \<33% of pleural malignancies shed malignant cells to the pleural fluid. even so, additional tissue biopsies are needed for establishing mutation status for targeted therapies. optimal imaging to guide tissue sampling is pivotal. pet-ct has higher sensitivity than conventional ct for detecting malignant lesions \>10mm. however, no randomised trial has investigated differences in diagnostic accuracy, time-to-diagnosis, or economics. falsely pet-positive lesions in e.g. colon, however, lead to more derived tests than do ct alone. gold standard for pleural tissue sampling is the surgical (vats) thoracoscopy, allowing direct visual guiding of tissue sampling from all pleural surfaces. yet, globally the medical (pleuroscopy) thoracoscopy is more widely used: cheaper, outpatient procedure, but allows only sampling from the parietal pleura. to date, no randomised studies have compared medical and surgical thoracoscopy concerning diagnostic hit rates, adverse events, or economics. investigators will perform two randomized studies to investigate whether 1. pet/ct is comparable to ct alone 2. vats is comparable to pleuroscopy concerning hit rate, total investigations performed, time-to-diagnosis.


Eligibility criteria:
inclusion criteria: 1. patients with recurrent pleural effusion of unknown origin after a first pleural tap according to bts guidelines. 2. indication for thoracoscopy according to bts guidelines. 3. patients accept further investigation according to danish and bts guidelines. 4. have received oral and written consent and agreed. 5. at the time of inclusion, above 18 years of age. exclusion criteria: 1. female patients: pregnancy or breastfeeding. 2. lack of language comprehension. 3. legally incompetent patients. 4. life expectancy less than 3 month. 5. contraindications to pleural tissue sampling.

Keywords: thoracoscopy